Close Menu

NEW YORK – A noninvasive molecular diagnostic test to anticipate heart transplant rejection has shown to have a nearly 100 percent negative predictive value in a recent evaluation.

Developed by Milwaukee, Wisconsin-based TAI Diagnostics, the laboratory-developed test uses fraction cell-free donor DNA in a recipient's blood as a biomarker of heart transplant viability. The assay, called MyTAIHeart, is the company's first though TAI Diagnostics is also developing longitudinal monitoring tests for other types of solid organ transplants.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.